<DOC>
	<DOCNO>NCT01697631</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare glycaemic control biphasic insulin aspart 30 ( BIAsp 30 ) alone combine insulin aspart ( IAsp ) patient previously treat conventional Biphasic Human Insulin 30/70 .</brief_summary>
	<brief_title>Glycemic Control Biphasic Insulin Aspart 30 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Current treatment conventional biphasic human insulin 30/70 b.i.d . ( twice daily ) least 3 month HbA1c ( glycosylated haemoglobin ) equal 12 % Willing able perform self blood glucose monitoring ( SMBG ) History drug alcohol dependence Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation Previous participation trial Receipt investigational drug within last month prior trial Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>